Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[The small molecule ET(A)R antagonist achieves concomitant suppression of tumor growth and EMT effectors, providing a new opportunity for therapeutic intervention in which targeting ILK pathway and the related Snail and beta-catenin signaling cascade via ET(A)R blockade may be advantageous in the treatment of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP906796.RACQggQw1eZyDhiOK3ff3rBmDnEKOu3oto4RMXxeLmLcM130_assertion description "[The small molecule ET(A)R antagonist achieves concomitant suppression of tumor growth and EMT effectors, providing a new opportunity for therapeutic intervention in which targeting ILK pathway and the related Snail and beta-catenin signaling cascade via ET(A)R blockade may be advantageous in the treatment of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP906796.RACQggQw1eZyDhiOK3ff3rBmDnEKOu3oto4RMXxeLmLcM130_provenance.
• NP551142.RAAmmsKcYxcIWmiEzfLStCcqRKQmpbJMv-C5RpjTqiGao130_assertion description "[The small molecule ET(A)R antagonist achieves concomitant suppression of tumor growth and EMT effectors, providing a new opportunity for therapeutic intervention in which targeting ILK pathway and the related Snail and beta-catenin signaling cascade via ET(A)R blockade may be advantageous in the treatment of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP551142.RAAmmsKcYxcIWmiEzfLStCcqRKQmpbJMv-C5RpjTqiGao130_provenance.
• NP525584.RAsWVMuQJ1mXA2usLcgWik3ENZbpoCEWWpa5O4aCKLyo0130_assertion description "[The small molecule ET(A)R antagonist achieves concomitant suppression of tumor growth and EMT effectors, providing a new opportunity for therapeutic intervention in which targeting ILK pathway and the related Snail and beta-catenin signaling cascade via ET(A)R blockade may be advantageous in the treatment of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP525584.RAsWVMuQJ1mXA2usLcgWik3ENZbpoCEWWpa5O4aCKLyo0130_provenance.
• NP280349.RAjWP1fd54EmJV7RdmoWrdZ0rRtLP1BKMNzMPJELGF6UY130_assertion description "[The small molecule ET(A)R antagonist achieves concomitant suppression of tumor growth and EMT effectors, providing a new opportunity for therapeutic intervention in which targeting ILK pathway and the related Snail and beta-catenin signaling cascade via ET(A)R blockade may be advantageous in the treatment of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP280349.RAjWP1fd54EmJV7RdmoWrdZ0rRtLP1BKMNzMPJELGF6UY130_provenance.
• NP788133.RAkTRZq_BLD7q0tCcrrMvRwEAvP6thHJMlA8Hmu48tivo130_assertion description "[The small molecule ET(A)R antagonist achieves concomitant suppression of tumor growth and EMT effectors, providing a new opportunity for therapeutic intervention in which targeting ILK pathway and the related Snail and beta-catenin signaling cascade via ET(A)R blockade may be advantageous in the treatment of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP788133.RAkTRZq_BLD7q0tCcrrMvRwEAvP6thHJMlA8Hmu48tivo130_provenance.
• NP365566.RAuw3HrIYphXpWrtvFzf5_FGopKCoW3ISRCvgtxejYPdM130_assertion description "[The small molecule ET(A)R antagonist achieves concomitant suppression of tumor growth and EMT effectors, providing a new opportunity for therapeutic intervention in which targeting ILK pathway and the related Snail and beta-catenin signaling cascade via ET(A)R blockade may be advantageous in the treatment of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP365566.RAuw3HrIYphXpWrtvFzf5_FGopKCoW3ISRCvgtxejYPdM130_provenance.
• NP616576.RAb_S7XJOKh0Rul2zfBpJpglcyw4zS9hV4DIkU9QueTro130_assertion description "[The small molecule ET(A)R antagonist achieves concomitant suppression of tumor growth and EMT effectors, providing a new opportunity for therapeutic intervention in which targeting ILK pathway and the related Snail and beta-catenin signaling cascade via ET(A)R blockade may be advantageous in the treatment of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP616576.RAb_S7XJOKh0Rul2zfBpJpglcyw4zS9hV4DIkU9QueTro130_provenance.
• NP709684.RAHi_74frCc_lZFllXO_SkD6lQjyERy-v8zHa-FOUT764130_assertion description "[The small molecule ET(A)R antagonist achieves concomitant suppression of tumor growth and EMT effectors, providing a new opportunity for therapeutic intervention in which targeting ILK pathway and the related Snail and beta-catenin signaling cascade via ET(A)R blockade may be advantageous in the treatment of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP709684.RAHi_74frCc_lZFllXO_SkD6lQjyERy-v8zHa-FOUT764130_provenance.
• NP365407.RACVJCj5Es7HPwS7t1IZbYWWa-dt_02dU2B8Pzzf8rRec130_assertion description "[The small molecule ET(A)R antagonist achieves concomitant suppression of tumor growth and EMT effectors, providing a new opportunity for therapeutic intervention in which targeting ILK pathway and the related Snail and beta-catenin signaling cascade via ET(A)R blockade may be advantageous in the treatment of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP365407.RACVJCj5Es7HPwS7t1IZbYWWa-dt_02dU2B8Pzzf8rRec130_provenance.
• NP616578.RAiSUz0jQCCobQaiPAhz_IGbO4Hz7jEoNwlm8FVBU234I130_assertion description "[The small molecule ET(A)R antagonist achieves concomitant suppression of tumor growth and EMT effectors, providing a new opportunity for therapeutic intervention in which targeting ILK pathway and the related Snail and beta-catenin signaling cascade via ET(A)R blockade may be advantageous in the treatment of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP616578.RAiSUz0jQCCobQaiPAhz_IGbO4Hz7jEoNwlm8FVBU234I130_provenance.
• NP509324.RAOfYyGQ-oH9Y3jJNdpgPCEjJRV_TL2DYofV-k5pmksiI130_assertion description "[The small molecule ET(A)R antagonist achieves concomitant suppression of tumor growth and EMT effectors, providing a new opportunity for therapeutic intervention in which targeting ILK pathway and the related Snail and beta-catenin signaling cascade via ET(A)R blockade may be advantageous in the treatment of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP509324.RAOfYyGQ-oH9Y3jJNdpgPCEjJRV_TL2DYofV-k5pmksiI130_provenance.
• NP509434.RAMX0jaftsIFyIc9aon6gFpYA6zV-WTw_x917ZTj2CXXM130_assertion description "[The small molecule ET(A)R antagonist achieves concomitant suppression of tumor growth and EMT effectors, providing a new opportunity for therapeutic intervention in which targeting ILK pathway and the related Snail and beta-catenin signaling cascade via ET(A)R blockade may be advantageous in the treatment of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP509434.RAMX0jaftsIFyIc9aon6gFpYA6zV-WTw_x917ZTj2CXXM130_provenance.
• NP616573.RAE3F9kmxAHTIHtMe42BbpCWpU0hZF4CG7aD532pzuvW8130_assertion description "[The small molecule ET(A)R antagonist achieves concomitant suppression of tumor growth and EMT effectors, providing a new opportunity for therapeutic intervention in which targeting ILK pathway and the related Snail and beta-catenin signaling cascade via ET(A)R blockade may be advantageous in the treatment of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP616573.RAE3F9kmxAHTIHtMe42BbpCWpU0hZF4CG7aD532pzuvW8130_provenance.
• NP616582.RAwnQZWagJOQBGigv4KtagJl465o9aCJXbYz_Jta18nso130_assertion description "[The small molecule ET(A)R antagonist achieves concomitant suppression of tumor growth and EMT effectors, providing a new opportunity for therapeutic intervention in which targeting ILK pathway and the related Snail and beta-catenin signaling cascade via ET(A)R blockade may be advantageous in the treatment of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP616582.RAwnQZWagJOQBGigv4KtagJl465o9aCJXbYz_Jta18nso130_provenance.